Dengue Vaccine Candidate Meets Primary Efficacy Endpoint in Phase 3 Study - Contagionlive.com

Dengue Vaccine Candidate Meets Primary Efficacy Endpoint in Phase 3 Study  Contagionlive.com

Takeda Pharmaceutical Company Limited has announced that an investigational dengue vaccine has met the primary efficacy endpoint in an ongoing Phase 3 ...



Comments

Popular posts from this blog

UConn Health's Caryl Ryan Recognized as Infection Prevention ... - University of Connecticut

Marburg virus disease